Efficacy and Safety of Tongren-Dahuoluo Bolus in Patients with Knee Osteoarthritis

Inclusion criteria

• Male or female, aged 40 to 75 years old;
• Meet the diagnostic criteria for primary knee osteoarthritis (KOA) (the diagnostic criteria refer to the 1995 American College of Rheumatology classification criteria for knee osteoarthritis);
• Meet the diagnostic criteria for liver and kidney deficiency and (or) cold and dampness obstruction in the group standard of the Chinese Association of Traditional Chinese Medicine "Guidelines for Combination of Osteoarthritis Symptoms";
• X-ray examination of the joints is graded as I to III (knee joint Kellgren/Lawrence e scoring standard);
• Knee pain score ≥40mm in the past week (assessed by VAS standard);

Exclusion criteria

• Patients with other rheumatic diseases such as Sjögren's syndrome, gout, rheumatoid arthritis, or a history of human immunodeficiency virus (HIV);
• Patients with severe lesions of important organs such as the heart, liver, and kidney, abnormal liver function (alanine or aspartate aminotransferase or glutamine transpeptidase>1.5 times the upper limit of normal value); or abnormal renal function (serum creatinine level> upper limit of normal value); white blood cell (white blood cell, WBC) or platelet (platelet, PLT) below the lower limit of normal value; or diabetic patients with poor blood sugar control in the recent period (glycosylated hemoglobin>8.0%);
• Patients with suppurative, nonspecific, and other infectious knee arthritis;
• Patients with traumatic, villonodular pigmentation and other lesions with knee synovium as the main lesions;
• Patients with advanced joint deformity or disability; A randomized controlled study on Tongren Dahuoluowan in the treatment of knee osteoarthritis Version number: 2023009P8A01 Version date: December 23, 2022
• Allergic constitution and allergic to the test drug;
• Pregnant, pregnant, or lactating women;
• Those who are taking antidepressants, anticonvulsants, opioids, sedatives and glucocorticoids;
• Patients who have received intra-articular treatment with sodium hyaluronate within 4 weeks before screening; those who have taken drugs containing chondroitin sulfate/glucosamine/diacerein within 3 months before screening; those who have used biological agents within 3 months before screening;
• Patients with organ failure symptoms;
• Those who have participated in any other drug trials within 1 month before selection;
• Those who the researcher believes are not eligible to join this clinical trial